The Lancet: November 16, 2007

Arne Astrup from the University of Copenhagen, Denmark, discusses a meta-analysis highlighting how the anti-obesity drug rimonabant is associated with an increased risk of depressive disorders. The meta-analysis pooled data from four randomised trials from the RIO (rimonabant in obesity) programme.
Source: Listen to The Lancet - Category: General Medicine Authors: Source Type: podcasts